BLAINJECTIONINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NYVEPRIA (pegfilgrastim-apgf) by Pfizer is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. First approved in 2020.
Drug data last refreshed 36m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYVEPRIA (pegfilgrastim-apgf) is a pegylated granulocyte colony-stimulating factor (G-CSF) biosimilar approved by FDA in June 2020. It stimulates proliferation and differentiation of hematopoietic cells by binding to specific cell surface receptors, reducing chemotherapy-induced neutropenia (CINP) risk. The drug is indicated for patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies.
$0.004BPart D
PeakProduct is in peak commercial phase with moderate biosimilar market competition; brand teams focus on maintaining market share and driving switching from reference products.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NYVEPRIA positions career professionals in competitive biosimilar commercialization with emphasis on payer relations, formulary management, and cost-of-care messaging. Career growth depends on execution in a price-sensitive, mature market segment with ongoing biosimilar competitive pressure.
Account Executive
Worked on NYVEPRIA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.